30 min
Pfizer CEO & Taking on Omicron Squawk Pod
-
- Investing
Pfizer CEO Albert Bourla says he’s “very, very confident” that the company’s Covid-19 treatment pill will be effective against the omicron variant of Covid-19, and that Pfizer will be able to manufacture a vaccine for this variant within 100 days, to be used if necessary. Pfizer submitted its application earlier this month to the Food and Drug Administration to authorize the pill, Paxlovid, for emergency use. Bourla spoke with CNBC’s Meg Tirrell and the ‘Squawk Box’ team to discuss managing the new variant. Plus, oil prices jumped today as traders bet that Friday’s sharp sell-off was overdone. CNBC’s Brian Sullivan reports on how the omicron Covid variant concerns are impacting energy markets.
In this episode:
Albert Bourla, @AlbertBourla
Brian Sullivan, @SullyCNBC
Joe Kernen, @JoeSquawk
Becky Quick, @BeckyQuick
Andrew Ross Sorkin, @andrewrsorkin
Katie Kramer, @Kramer_Katie
Pfizer CEO Albert Bourla says he’s “very, very confident” that the company’s Covid-19 treatment pill will be effective against the omicron variant of Covid-19, and that Pfizer will be able to manufacture a vaccine for this variant within 100 days, to be used if necessary. Pfizer submitted its application earlier this month to the Food and Drug Administration to authorize the pill, Paxlovid, for emergency use. Bourla spoke with CNBC’s Meg Tirrell and the ‘Squawk Box’ team to discuss managing the new variant. Plus, oil prices jumped today as traders bet that Friday’s sharp sell-off was overdone. CNBC’s Brian Sullivan reports on how the omicron Covid variant concerns are impacting energy markets.
In this episode:
Albert Bourla, @AlbertBourla
Brian Sullivan, @SullyCNBC
Joe Kernen, @JoeSquawk
Becky Quick, @BeckyQuick
Andrew Ross Sorkin, @andrewrsorkin
Katie Kramer, @Kramer_Katie
30 min